Remove Article Remove Eating disorders Remove Sleep and mental health
article thumbnail

Introducing the Borderline Personality Disorder Inventory

Psychiatric Times

Developed with input from international mental health professionals, the BPD-I™ is freely available for clinical use, education, and research. SHOW MORE Discover the innovative Borderline Personality Disorder Inventory (BPD-I™), a psychodynamically-informed tool for assessing BPD symptoms effectively.

article thumbnail

What Is a Sleep Disorder? A Harmful Dysfunction Analysis

Psychiatric Times

A Harmful Dysfunction Analysis Author(s): Jean-Arthur Micoulaud-Franchi, MD, PhD , Christophe Gauld, MD, PhD +2 More Key Takeaways Sleep medicine lacks a structured definition for disorders, complicating diagnosis and classification compared to psychiatry's DSM framework. SHOW MORE What is a sleep disorder?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

sNDA Submitted: Lumateperone for the Prevention of Relapse in Schizophrenia

Psychiatric Times

Knoll IV, MD July 1st 2025 Positive Results From the Phase 2b Study of BPL-003 in Patients With Treatment-Resistant Depression Leah Kuntz May 11th 2021 More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle Anita H.

article thumbnail

FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD

Psychiatric Times

SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Healthcare professionals should monitor weight and growth in young patients on these medications and consider alternative treatments if adverse effects occur.

article thumbnail

Brief Book Reviews: July 2025

Psychiatric Times

Higgins, MD These 2 compelling memoirs delve into the complexities of schizophrenia, showcasing resilience, friendship, and the impact of mental health. While this is an extraordinary accomplishment for someone with a serious mental illness, reading between the lines, it seems that Laudor lost some cognitive skills due to the illness.

article thumbnail

COMP360 Psilocybin for Treatment-Resistant Depression: Positive Phase 3 Efficacy Data

Psychiatric Times

The COMP005 trial is the first phase 3 study of synthetic psilocybin, marking a milestone in psychedelic research for mental health. No unexpected safety issues or imbalance in suicidal ideation were observed between treatment and placebo groups. points (95% CI [-5.7, -1.5]) in change at the primary endpoint.

article thumbnail

NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100)

Psychiatric Times

1 The newly announced CNPV pathway was introduced by FDA Commissioner Marty Makary, MD, MPH, on June 17, 2025, and is intended to expedite reviews for medications that address US public health priorities. The CNPV program, introduced by FDA Commissioner Marty Makary, aims to reduce review times to 1-2 months for eligible applications.